Turn Therapeutics (TTRX) Common Equity (2024 - 2026)

Turn Therapeutics' Common Equity history runs 3 years deep, the most recent figure standing at $6.1 million for Q1 2026.

• On a quarterly basis, Common Equity rose 647.22% year-over-year to $6.1 million in Q1 2026; TTM through Mar 2026 was $6.1 million, a 647.22% increase from a year earlier, with the FY2025 full-year figure at $4.7 million, up 2741.42% from the prior year.
• Common Equity advanced to $6.1 million in Q1 2026 per TTRX's latest filing, from $4.7 million in the prior quarter.
• Across five years, Common Equity topped out at $6.1 million in Q1 2026 and bottomed at -$414299.0 in Q3 2024.
• The 3-year median for Common Equity is $435704.5 (2025), against an average of $1.8 million.
• Biggest YoY gain for Common Equity was 2741.42% in 2025; the steepest drop was 112.72% in 2025.
• Year by year, Common Equity stood at -$177432.0 in 2024, then soared by 2741.42% to $4.7 million in 2025, then jumped by 30.53% to $6.1 million in 2026.
• Per Business Quant, the three latest TTRX Common Equity figures stand at $6.1 million (Q1 2026), $4.7 million (Q4 2025), and $52699.0 (Q3 2025).